Ortin Global(ORTINGLOBE)株式概要オルティン・グローバル・リミテッドはインドで医薬品、薬剤、中間体の製造と取引を行っている。 詳細ORTINGLOBE ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析キャッシュランウェイが1年未満である 収益が 100 万ドル未満 ( ₹1M )過去5年間で収益は年間27.8%減少しました。 意味のある時価総額がありません ( ₹146M )すべてのリスクチェックを見るORTINGLOBE Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹18.021.3k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-80m2b2016201920222025202620282031Revenue ₹13.2mEarnings ₹1.9mAdvancedSet Fair ValueView all narrativesOrtin Global Limited 競合他社Shamrock IndustrialSymbol: BSE:531240Market cap: ₹127.8mStarsource MultitradeSymbol: BSE:506365Market cap: ₹178.4mCian HealthcareSymbol: BSE:542678Market cap: ₹206.5mBeryl DrugsSymbol: BSE:524606Market cap: ₹123.0m価格と性能株価の高値、安値、推移の概要Ortin Global過去の株価現在の株価₹18.0252週高値₹21.3052週安値₹10.66ベータ0.481ヶ月の変化20.13%3ヶ月変化9.21%1年変化62.78%3年間の変化-25.38%5年間の変化-50.36%IPOからの変化-33.72%最新ニュースReported Earnings • May 31Full year 2026 earnings released: ₹0.91 loss per share (vs ₹1.04 loss in FY 2025)Full year 2026 results: ₹0.91 loss per share (improved from ₹1.04 loss in FY 2025). Net loss: ₹7.40m (loss narrowed 13% from FY 2025). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • May 25Ortin Global Limited to Report Q4, 2026 Results on May 30, 2026Ortin Global Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026Reported Earnings • Feb 15Third quarter 2026 earnings released: ₹0.07 loss per share (vs ₹0.13 loss in 3Q 2025)Third quarter 2026 results: ₹0.07 loss per share (improved from ₹0.13 loss in 3Q 2025). Net loss: ₹532.0k (loss narrowed 50% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.お知らせ • Feb 05Ortin Global Limited to Report Q3, 2026 Results on Feb 14, 2026Ortin Global Limited announced that they will report Q3, 2026 results on Feb 14, 2026New Risk • Dec 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹9.2m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (₹1.7m revenue, or US$19k). Market cap is less than US$10m (₹116.8m market cap, or US$1.30m). Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change).Reported Earnings • Nov 17Second quarter 2026 earnings released: ₹0.62 loss per share (vs ₹0.58 loss in 2Q 2025)Second quarter 2026 results: ₹0.62 loss per share (further deteriorated from ₹0.58 loss in 2Q 2025). Net loss: ₹5.03m (loss widened 6.4% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 20% per year.最新情報をもっと見るRecent updatesReported Earnings • May 31Full year 2026 earnings released: ₹0.91 loss per share (vs ₹1.04 loss in FY 2025)Full year 2026 results: ₹0.91 loss per share (improved from ₹1.04 loss in FY 2025). Net loss: ₹7.40m (loss narrowed 13% from FY 2025). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.お知らせ • May 25Ortin Global Limited to Report Q4, 2026 Results on May 30, 2026Ortin Global Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026Reported Earnings • Feb 15Third quarter 2026 earnings released: ₹0.07 loss per share (vs ₹0.13 loss in 3Q 2025)Third quarter 2026 results: ₹0.07 loss per share (improved from ₹0.13 loss in 3Q 2025). Net loss: ₹532.0k (loss narrowed 50% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.お知らせ • Feb 05Ortin Global Limited to Report Q3, 2026 Results on Feb 14, 2026Ortin Global Limited announced that they will report Q3, 2026 results on Feb 14, 2026New Risk • Dec 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹9.2m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (₹1.7m revenue, or US$19k). Market cap is less than US$10m (₹116.8m market cap, or US$1.30m). Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change).Reported Earnings • Nov 17Second quarter 2026 earnings released: ₹0.62 loss per share (vs ₹0.58 loss in 2Q 2025)Second quarter 2026 results: ₹0.62 loss per share (further deteriorated from ₹0.58 loss in 2Q 2025). Net loss: ₹5.03m (loss widened 6.4% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 20% per year.お知らせ • Nov 08Ortin Global Limited to Report Q2, 2026 Results on Nov 14, 2025Ortin Global Limited announced that they will report Q2, 2026 results on Nov 14, 2025お知らせ • Sep 08Ortin Global Limited, Annual General Meeting, Sep 30, 2025Ortin Global Limited, Annual General Meeting, Sep 30, 2025, at 16:00 Indian Standard Time.お知らせ • Aug 27Ortin Global Limited Approves Board AppointmentsOrtin Global Limited at its EGM held on August 25, 2025 approved appointment of Mr. Sarang Balbhimrao Patodekar as chairperson and independent director of the company, Mr. Ajay Vishwakarma as an independent director of the company, Ms' Mounika Pammi as an independent director of the company, Mr. prashant prakash Sawant as a director and Whole-time director of the company and Mrs. Prakruti Prashant Sawant as a director and whole-time director of the company.Reported Earnings • Aug 16First quarter 2026 earnings released: ₹0.22 loss per share (vs ₹0.13 loss in 1Q 2025)First quarter 2026 results: ₹0.22 loss per share (further deteriorated from ₹0.13 loss in 1Q 2025). Net loss: ₹1.75m (loss widened 70% from 1Q 2025).New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹4.1m free cash flow). Earnings have declined by 60% per year over the past 5 years. Revenue is less than US$1m (₹3.8m revenue, or US$44k). Market cap is less than US$10m (₹122.1m market cap, or US$1.39m). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).お知らせ • Aug 09Ortin Global Limited to Report Q1, 2026 Results on Aug 14, 2025Ortin Global Limited announced that they will report Q1, 2026 results on Aug 14, 2025Board Change • Aug 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Additional Non-Executive Director Shashikant Igave is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jul 10+ 1 more updateOrtin Global Limited Announces Directorate Resignation and Reconstitution of Committees of the Board, Effective July 10, 2025Ortin Global Limited at its board meeting held on July 10, 2025, approved: Resignation of Mr. Murali Krishna Rayaprolu, Chairperson and Independent Director of the Company effective July 10, 2025, due to his other professional and personal reasons. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter. Resignation of Mr. Ramesh Joshi, as Whole-time Director of the Company effective July 10, 2025, due to his other professional and personal reasons. (Resignation Letter is enclosed) Resignation of Ms. Pottur Sujatha, Independent Director of the Company effective July 10, 2025, due to her other professional and personal reasons. She has confirmed that there are no other material reasons for her resignation other than that mentioned in her resignation letter. Resignation of Ms. Smitaben Suthar, Independent Director of the Company effective July 10, 2025, due to her other professional and personal reasons. She has confirmed that there are no other material reasons for her resignation other than that mentioned in her resignation letter. Resignation of Mr. Pratik Bharatbhai Panchal, Independent Director of the Company effective July 10, 2025, due to his other professional and personal reasons. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter. Resignation of Mr. Ritvikbhai Mukeshbhai Beladiya, Non-Executive Non Independent Director of the Company effective July 10, 2025, due to his other professional and personal reasons. Reconstitution of Committees of the Board as under: The Audit Committee consists of the following members: Mr. Sarang Balbhimrao Patodekar serves as the Chairperson, while Mr. Ajay Vishwakarma and Ms. Mounika Pammi are both designated as Members. The committee is composed of the following members: Ms. Mounika Pammi serves as the Chairperson, while Mr. Ajay Vishwakarma and Mr. Sarang Balbhimrao Patodekar are both designated as Members. The Stakeholders Relationship Committee is comprised of the following members: Mr. Sarang Balbhimrao Patodekar serves as the Chairperson, while Mr. Ajay Vishwakarma and Ms. Mounika Pammi are both designated as Members.Reported Earnings • May 28Full year 2025 earnings released: ₹1.04 loss per share (vs ₹9.89 loss in FY 2024)Full year 2025 results: ₹1.04 loss per share (improved from ₹9.89 loss in FY 2024). Revenue: ₹3.84m (down 82% from FY 2024). Net loss: ₹8.46m (loss narrowed 90% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.お知らせ • May 19Ortin Global Limited to Report Q4, 2025 Results on May 26, 2025Ortin Global Limited announced that they will report Q4, 2025 results on May 26, 2025New Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹58m free cash flow). Earnings have declined by 64% per year over the past 5 years. Revenue is less than US$1m (₹4.4m revenue, or US$51k). Market cap is less than US$10m (₹100.3m market cap, or US$1.16m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).Reported Earnings • Feb 14Third quarter 2025 earnings released: ₹0.13 loss per share (vs ₹3.43 loss in 3Q 2024)Third quarter 2025 results: ₹0.13 loss per share (improved from ₹3.43 loss in 3Q 2024). Revenue: ₹335.0k (down 75% from 3Q 2024). Net loss: ₹1.07m (loss narrowed 96% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.お知らせ • Feb 07Ortin Global Limited to Report Q3, 2025 Results on Feb 12, 2025Ortin Global Limited announced that they will report Q3, 2025 results on Feb 12, 2025Reported Earnings • Nov 15Second quarter 2025 earnings released: ₹58.00 loss per share (vs ₹1.38 loss in 2Q 2024)Second quarter 2025 results: ₹58.00 loss per share. Revenue: ₹525.0k (down 80% from 2Q 2024). Net loss: ₹4.72m (loss narrowed 58% from 2Q 2024).お知らせ • Nov 05Ortin Global Limited to Report Q2, 2025 Results on Nov 13, 2024Ortin Global Limited announced that they will report Q2, 2025 results on Nov 13, 2024お知らせ • Sep 13Ortin Global Limited, Annual General Meeting, Sep 30, 2024Ortin Global Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time.Reported Earnings • Aug 15First quarter 2025 earnings released: ₹0.13 loss per share (vs ₹0.02 profit in 1Q 2024)First quarter 2025 results: ₹0.13 loss per share (down from ₹0.02 profit in 1Q 2024). Revenue: ₹2.11m (down 87% from 1Q 2024). Net loss: ₹1.03m (down ₹1.19m from profit in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.New Risk • Aug 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 59% per year over the past 5 years. Revenue is less than US$1m (₹21m revenue, or US$252k). Market cap is less than US$10m (₹162.6m market cap, or US$1.94m). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change).お知らせ • Aug 07Ortin Global Limited to Report Q1, 2025 Results on Aug 13, 2024Ortin Global Limited announced that they will report Q1, 2025 results on Aug 13, 2024お知らせ • Jul 18Ortin Laboratories Limited Announces Resignation of Divya Purswani as Company Secretary and Compliance OfficerOrtin Laboratories Limited announced that Mrs. Divya Purswani has resigned from the post of company secretary and compliance officer of the company with effect from 18 July 2024 (After close of Business hours) due to her personal reasons.Reported Earnings • Jun 04Full year 2024 earnings released: ₹9.89 loss per share (vs ₹0.12 loss in FY 2023)Full year 2024 results: ₹9.89 loss per share (further deteriorated from ₹0.12 loss in FY 2023). Revenue: ₹22.8m (down 62% from FY 2023). Net loss: ₹80.4m (loss widened ₹79.5m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.お知らせ • May 24Ortin Laboratories Limited to Report Q4, 2024 Results on May 30, 2024Ortin Laboratories Limited announced that they will report Q4, 2024 results on May 30, 2024Reported Earnings • Feb 14Third quarter 2024 earnings released: ₹3.43 loss per share (vs ₹0.56 profit in 3Q 2023)Third quarter 2024 results: ₹3.43 loss per share (down from ₹0.56 profit in 3Q 2023). Revenue: ₹1.37m (down 88% from 3Q 2023). Net loss: ₹27.9m (down ₹32.5m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.お知らせ • Feb 09Ortin Laboratories Limited Appoints Divya Purswani as Company Secretary and Compliance OfficerThe Board of Directors of Ortin Laboratories Limited at its meeting held on 9 February, 2024 has considered and approved the Appointment of Ms. Divya Purswani as Company Secretary and Compliance Officer of the Company with effect from February 09, 2024. Ms. Divya Purswani is a qualified Company Secretary, having working experience of around 2 years in the area of corporate laws and secretarial matters.お知らせ • Feb 07Ortin Laboratories Limited to Report Q3, 2024 Results on Feb 13, 2024Ortin Laboratories Limited announced that they will report Q3, 2024 results on Feb 13, 2024Buy Or Sell Opportunity • Jan 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 26% to ₹22.00. The fair value is estimated to be ₹18.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 65% over the last 3 years. Meanwhile, the company became loss making.Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pottur Sujatha was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 16Second quarter 2024 earnings releasedSecond quarter 2024 results: ₹1.38 loss per share. Revenue: ₹2.65m (down 66% from 2Q 2023). Net loss: ₹11.2m (down ₹12.0m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.お知らせ • Nov 12Ortin Laboratories Limited Announces Executive ChangesOrtin Laboratories Limited announced that Mr. Harish Sharma has resigned from the post of Company Secretary and Compliance officer with effect from 10 November 2023, due to his personal reasons. (After close of Business hours). Mr. S. Murali Krishna Murthy, Managing Director will act as the Compliance Officer of the Company till the appointment of new Company Secretary and Compliance Officer.お知らせ • Oct 11Ortin Laboratories Limited Appointment of Harish Sharma as Company SecretaryOrtin Laboratories Limited announced at the board meeting held on October 10, 2023, approved Appointment of Mr. Harish Sharma as Company Secretary and Compliance Officer of the Company with effect from 10.10.2023. Mr. Harish Sharma is a qualified Company Secretary, having working experience of around 4.5 years in the area of corporate laws and secretarial matters.お知らせ • Sep 07Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2023Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time.Reported Earnings • Aug 16First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: ₹0.02. Revenue: ₹15.7m (down 40% from 1Q 2023). Net income: ₹164.0k (up ₹4.43m from 1Q 2023). Profit margin: 1.0% (up from net loss in 1Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.お知らせ • Aug 05Ortin Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023Ortin Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023お知らせ • Jul 12Drugs Control Administration, Government of Telangana Cancels Manufacturing License of Ortin Laboratories LimitedOrtin Laboratories Limited announced that Drugs Control Administration, Government of Telangana vide its Order dated 03 July 2023 received by the Company on 11 July 2023 has cancelled the Company's Manufacturing License effective from July 11, 2023 forwant of upgradation of manufacturing facilities, infrastructure and recruiting expert technical team as per the provisions of Schedule-M of Drugs and Cosmetics Act, 1940 & rules made there under. Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any: Could not upgrade the manufacturing facilities, infrastructure and expert technical team as per the provisions of Schedule-M of Drugs and Cosmetics Act. 1940. Production of medicines is stopped and as a result there will be monetary impact to the tune of 75% of the turnover which is approximately INR 60 million. There is no other penalty involved or imposed on the company.お知らせ • Jun 14Ortin Laboratories Limited Announces Resignation of Nitesh Kumar Sharma as Company Secretary/Compliance OfficerOrtin Laboratories Limited informed that Mr. Nitesh Kumar Sharma has resigned from the post of Company Secretary and Compliance officer of the company with effect from June 12, 2023 (After close of Business hours). Mr. S. Murali Krishna Murthy, Managing Director will act as the Compliance Officer of the Company till the appointment of new Company Secretary and Compliance Officer.New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (₹61m revenue, or US$735k). Market cap is less than US$10m (₹186.9m market cap, or US$2.27m). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).Reported Earnings • Jun 03Full year 2023 earnings released: ₹0.08 loss per share (vs ₹0.49 loss in FY 2022)Full year 2023 results: ₹0.08 loss per share (improved from ₹0.49 loss in FY 2022). Revenue: ₹60.6m (down 26% from FY 2022). Net loss: ₹669.0k (loss narrowed 83% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.11 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹0.56 (up from ₹0.11 loss in 3Q 2022). Revenue: ₹11.7m (down 30% from 3Q 2022). Net income: ₹4.56m (up ₹5.46m from 3Q 2022). Profit margin: 39% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.お知らせ • Feb 01Ortin Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023Ortin Laboratories Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 14, 2023Reported Earnings • Nov 20Second quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.07 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.01. Revenue: ₹7.87m (down 66% from 2Q 2022). Net income: ₹808.0k (up 50% from 2Q 2022). Profit margin: 10% (up from 2.3% in 2Q 2022). The increase in margin was driven by lower expenses.Reported Earnings • Aug 19First quarter 2023 earnings released: ₹0.05 loss per share (vs ₹0.11 profit in 1Q 2022)First quarter 2023 results: ₹0.05 loss per share (down from ₹0.11 profit in 1Q 2022). Revenue: ₹26.2m (up 32% from 1Q 2022). Net loss: ₹4.27m (down ₹5.18m from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Reported Earnings • Jun 02Full year 2022 earnings released: ₹0.49 loss per share (vs ₹1.16 profit in FY 2021)Full year 2022 results: ₹0.49 loss per share (down from ₹1.16 profit in FY 2021). Revenue: ₹84.3m (up 2.5% from FY 2021). Net loss: ₹3.99m (down 142% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Executive Departure • Dec 05Whole Time Director Sanka Mohan Murthy has left the companyOn the 26th of November, Sanka Mohan Murthy's tenure as Whole Time Director ended after 10.8 years in the role. As of September 2021, Sanka Mohan still personally held only 13.62k shares (₹367k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹30.85, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 14% over the past three years.Reported Earnings • Jul 10Full year 2021 earnings released: EPS ₹1.16 (vs ₹0.69 loss in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: ₹82.2m (down 96% from FY 2020). Net income: ₹9.46m (up ₹15.1m from FY 2020). Profit margin: 12% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹36.30, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹25.35, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 18x in the Pharmaceuticals industry in India. Total returns to shareholders of 35% over the past three years.分析記事 • Jan 24Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention TodayLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹32.60, the stock is trading at a trailing P/E ratio of 22x, up from the previous P/E ratio of 17.3x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 19%.Valuation Update With 7 Day Price Move • Dec 31Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹30.00, the stock is trading at a trailing P/E ratio of 20.9x, up from the previous P/E ratio of 18x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 8.3%.Is New 90 Day High Low • Dec 31New 90-day high: ₹30.00The company is up 54% from its price of ₹19.45 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period.分析記事 • Dec 27Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Dec 03Market bids up stock over the past weekAfter last week's 17% share price gain to ₹25.60, the stock is trading at a trailing P/E ratio of 18x, up from the previous P/E ratio of 15.4x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 35%.分析記事 • Nov 30Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?Most readers would already be aware that Ortin Laboratories' (NSE:ORTINLABSS) stock increased significantly by 12...Is New 90 Day High Low • Nov 18New 90-day high: ₹23.15The company is up 4.0% from its price of ₹22.30 on 20 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.分析記事 • Sep 15Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt LoadThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...株主還元ORTINGLOBEIN PharmaceuticalsIN 市場7D14.9%1.2%-0.7%1Y62.8%6.7%-4.3%株主還元を見る業界別リターン: ORTINGLOBE過去 1 年間で6.7 % の収益を上げたIndian Pharmaceuticals業界を上回りました。リターン対市場: ORTINGLOBE過去 1 年間で-4.3 % の収益を上げたIndian市場を上回りました。価格変動Is ORTINGLOBE's price volatile compared to industry and market?ORTINGLOBE volatilityORTINGLOBE Average Weekly Movement8.5%Pharmaceuticals Industry Average Movement7.1%Market Average Movement7.2%10% most volatile stocks in IN Market10.2%10% least volatile stocks in IN Market4.7%安定した株価: ORTINGLOBE 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: ORTINGLOBEの 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO(最高経営責任者ウェブサイト19863Sanka Murali Murthywww.ortinlabsindia.comオルティン・グローバル・リミテッドは、インドで医薬品、薬剤、中間体の製造と取引を行っている。製造部門と貿易部門を通じて事業を展開している。同社は、錠剤、カプセル剤、シロップ剤、乾燥粉末剤などの様々な医薬品製剤を提供している。製剤には、抗糖尿病薬、抗アレルギー薬、抗狭心症薬、抗循環器薬、鎮静薬、精神安定薬、鎮痛薬、解熱薬、抗バイオティクス-キノロン系抗菌薬、抗バイオティクス-ペンシル系抗菌薬、抗真菌薬、セファロスポリン系抗菌薬、マクロライド系抗菌薬などがある。また、化学療法剤、制酸剤・抗潰瘍剤、抗痙攣剤、カルシウム・鉄剤、抗関節炎剤、タンパク質サプリメント、酵素、ビタミン剤、精神科、食欲増進剤、婦人科、抗レトロウイルス剤なども取り扱っている。また、抗レトロウイルス薬、抗糖尿病薬、鎮痛・解熱薬、抗生物質、抗真菌薬、制酸・抗潰瘍薬、抗マラリア薬などの原薬中間体や、ファインケミカル、グリニャールおよびアルカリ金属製品の製造も行っている。さらに、プロセス開発、プロセスおよび製品の特性評価、分析研究開発、アッセイ開発、新製剤ブランドの研究開発サービス、ラピッドフローキット、アッセイ、試薬の開発からなる診断サービスの分野でもサービスを提供している。また、中間体製造や新規原薬開発の長期契約、医薬品完成品の輸出業者、不動産事業も行っている。旧社名はオルチン・ラボラトリーズ・リミテッドで、2024年6月にオルチン・グローバル・リミテッドに社名変更した。オルチン・グローバル・リミテッドは1986年に設立され、本社はインドのハイデラバードにある。もっと見るOrtin Global Limited 基礎のまとめOrtin Global の収益と売上を時価総額と比較するとどうか。ORTINGLOBE 基礎統計学時価総額₹146.37m収益(TTM)-₹7.40m売上高(TTM)₹1.01m145.6xP/Sレシオ-19.8xPER(株価収益率ORTINGLOBE は割高か?公正価値と評価分析を参照収益と収入最新の決算報告書(TTM)に基づく主な収益性統計ORTINGLOBE 損益計算書(TTM)収益₹1.01m売上原価₹965.00k売上総利益₹40.00kその他の費用₹7.44m収益-₹7.40m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益(EPS)-0.91グロス・マージン3.98%純利益率-736.72%有利子負債/自己資本比率81.2%ORTINGLOBE の長期的なパフォーマンスは?過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/06/10 17:34終値2026/06/10 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ortin Global Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 31Full year 2026 earnings released: ₹0.91 loss per share (vs ₹1.04 loss in FY 2025)Full year 2026 results: ₹0.91 loss per share (improved from ₹1.04 loss in FY 2025). Net loss: ₹7.40m (loss narrowed 13% from FY 2025). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • May 25Ortin Global Limited to Report Q4, 2026 Results on May 30, 2026Ortin Global Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026
Reported Earnings • Feb 15Third quarter 2026 earnings released: ₹0.07 loss per share (vs ₹0.13 loss in 3Q 2025)Third quarter 2026 results: ₹0.07 loss per share (improved from ₹0.13 loss in 3Q 2025). Net loss: ₹532.0k (loss narrowed 50% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.
お知らせ • Feb 05Ortin Global Limited to Report Q3, 2026 Results on Feb 14, 2026Ortin Global Limited announced that they will report Q3, 2026 results on Feb 14, 2026
New Risk • Dec 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹9.2m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (₹1.7m revenue, or US$19k). Market cap is less than US$10m (₹116.8m market cap, or US$1.30m). Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change).
Reported Earnings • Nov 17Second quarter 2026 earnings released: ₹0.62 loss per share (vs ₹0.58 loss in 2Q 2025)Second quarter 2026 results: ₹0.62 loss per share (further deteriorated from ₹0.58 loss in 2Q 2025). Net loss: ₹5.03m (loss widened 6.4% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 20% per year.
Reported Earnings • May 31Full year 2026 earnings released: ₹0.91 loss per share (vs ₹1.04 loss in FY 2025)Full year 2026 results: ₹0.91 loss per share (improved from ₹1.04 loss in FY 2025). Net loss: ₹7.40m (loss narrowed 13% from FY 2025). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
お知らせ • May 25Ortin Global Limited to Report Q4, 2026 Results on May 30, 2026Ortin Global Limited announced that they will report Q4, 2026 results at 3:30 PM, Indian Standard Time on May 30, 2026
Reported Earnings • Feb 15Third quarter 2026 earnings released: ₹0.07 loss per share (vs ₹0.13 loss in 3Q 2025)Third quarter 2026 results: ₹0.07 loss per share (improved from ₹0.13 loss in 3Q 2025). Net loss: ₹532.0k (loss narrowed 50% from 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.
お知らせ • Feb 05Ortin Global Limited to Report Q3, 2026 Results on Feb 14, 2026Ortin Global Limited announced that they will report Q3, 2026 results on Feb 14, 2026
New Risk • Dec 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹9.2m free cash flow). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (₹1.7m revenue, or US$19k). Market cap is less than US$10m (₹116.8m market cap, or US$1.30m). Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change).
Reported Earnings • Nov 17Second quarter 2026 earnings released: ₹0.62 loss per share (vs ₹0.58 loss in 2Q 2025)Second quarter 2026 results: ₹0.62 loss per share (further deteriorated from ₹0.58 loss in 2Q 2025). Net loss: ₹5.03m (loss widened 6.4% from 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 24% per year whereas the company’s share price has fallen by 20% per year.
お知らせ • Nov 08Ortin Global Limited to Report Q2, 2026 Results on Nov 14, 2025Ortin Global Limited announced that they will report Q2, 2026 results on Nov 14, 2025
お知らせ • Sep 08Ortin Global Limited, Annual General Meeting, Sep 30, 2025Ortin Global Limited, Annual General Meeting, Sep 30, 2025, at 16:00 Indian Standard Time.
お知らせ • Aug 27Ortin Global Limited Approves Board AppointmentsOrtin Global Limited at its EGM held on August 25, 2025 approved appointment of Mr. Sarang Balbhimrao Patodekar as chairperson and independent director of the company, Mr. Ajay Vishwakarma as an independent director of the company, Ms' Mounika Pammi as an independent director of the company, Mr. prashant prakash Sawant as a director and Whole-time director of the company and Mrs. Prakruti Prashant Sawant as a director and whole-time director of the company.
Reported Earnings • Aug 16First quarter 2026 earnings released: ₹0.22 loss per share (vs ₹0.13 loss in 1Q 2025)First quarter 2026 results: ₹0.22 loss per share (further deteriorated from ₹0.13 loss in 1Q 2025). Net loss: ₹1.75m (loss widened 70% from 1Q 2025).
New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹4.1m free cash flow). Earnings have declined by 60% per year over the past 5 years. Revenue is less than US$1m (₹3.8m revenue, or US$44k). Market cap is less than US$10m (₹122.1m market cap, or US$1.39m). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change).
お知らせ • Aug 09Ortin Global Limited to Report Q1, 2026 Results on Aug 14, 2025Ortin Global Limited announced that they will report Q1, 2026 results on Aug 14, 2025
Board Change • Aug 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Additional Non-Executive Director Shashikant Igave is the most experienced director on the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jul 10+ 1 more updateOrtin Global Limited Announces Directorate Resignation and Reconstitution of Committees of the Board, Effective July 10, 2025Ortin Global Limited at its board meeting held on July 10, 2025, approved: Resignation of Mr. Murali Krishna Rayaprolu, Chairperson and Independent Director of the Company effective July 10, 2025, due to his other professional and personal reasons. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter. Resignation of Mr. Ramesh Joshi, as Whole-time Director of the Company effective July 10, 2025, due to his other professional and personal reasons. (Resignation Letter is enclosed) Resignation of Ms. Pottur Sujatha, Independent Director of the Company effective July 10, 2025, due to her other professional and personal reasons. She has confirmed that there are no other material reasons for her resignation other than that mentioned in her resignation letter. Resignation of Ms. Smitaben Suthar, Independent Director of the Company effective July 10, 2025, due to her other professional and personal reasons. She has confirmed that there are no other material reasons for her resignation other than that mentioned in her resignation letter. Resignation of Mr. Pratik Bharatbhai Panchal, Independent Director of the Company effective July 10, 2025, due to his other professional and personal reasons. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter. Resignation of Mr. Ritvikbhai Mukeshbhai Beladiya, Non-Executive Non Independent Director of the Company effective July 10, 2025, due to his other professional and personal reasons. Reconstitution of Committees of the Board as under: The Audit Committee consists of the following members: Mr. Sarang Balbhimrao Patodekar serves as the Chairperson, while Mr. Ajay Vishwakarma and Ms. Mounika Pammi are both designated as Members. The committee is composed of the following members: Ms. Mounika Pammi serves as the Chairperson, while Mr. Ajay Vishwakarma and Mr. Sarang Balbhimrao Patodekar are both designated as Members. The Stakeholders Relationship Committee is comprised of the following members: Mr. Sarang Balbhimrao Patodekar serves as the Chairperson, while Mr. Ajay Vishwakarma and Ms. Mounika Pammi are both designated as Members.
Reported Earnings • May 28Full year 2025 earnings released: ₹1.04 loss per share (vs ₹9.89 loss in FY 2024)Full year 2025 results: ₹1.04 loss per share (improved from ₹9.89 loss in FY 2024). Revenue: ₹3.84m (down 82% from FY 2024). Net loss: ₹8.46m (loss narrowed 90% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 44 percentage points per year, which is a significant difference in performance.
お知らせ • May 19Ortin Global Limited to Report Q4, 2025 Results on May 26, 2025Ortin Global Limited announced that they will report Q4, 2025 results on May 26, 2025
New Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹58m free cash flow). Earnings have declined by 64% per year over the past 5 years. Revenue is less than US$1m (₹4.4m revenue, or US$51k). Market cap is less than US$10m (₹100.3m market cap, or US$1.16m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
Reported Earnings • Feb 14Third quarter 2025 earnings released: ₹0.13 loss per share (vs ₹3.43 loss in 3Q 2024)Third quarter 2025 results: ₹0.13 loss per share (improved from ₹3.43 loss in 3Q 2024). Revenue: ₹335.0k (down 75% from 3Q 2024). Net loss: ₹1.07m (loss narrowed 96% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 07Ortin Global Limited to Report Q3, 2025 Results on Feb 12, 2025Ortin Global Limited announced that they will report Q3, 2025 results on Feb 12, 2025
Reported Earnings • Nov 15Second quarter 2025 earnings released: ₹58.00 loss per share (vs ₹1.38 loss in 2Q 2024)Second quarter 2025 results: ₹58.00 loss per share. Revenue: ₹525.0k (down 80% from 2Q 2024). Net loss: ₹4.72m (loss narrowed 58% from 2Q 2024).
お知らせ • Nov 05Ortin Global Limited to Report Q2, 2025 Results on Nov 13, 2024Ortin Global Limited announced that they will report Q2, 2025 results on Nov 13, 2024
お知らせ • Sep 13Ortin Global Limited, Annual General Meeting, Sep 30, 2024Ortin Global Limited, Annual General Meeting, Sep 30, 2024, at 11:00 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2025 earnings released: ₹0.13 loss per share (vs ₹0.02 profit in 1Q 2024)First quarter 2025 results: ₹0.13 loss per share (down from ₹0.02 profit in 1Q 2024). Revenue: ₹2.11m (down 87% from 1Q 2024). Net loss: ₹1.03m (down ₹1.19m from profit in 1Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance.
New Risk • Aug 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 59% per year over the past 5 years. Revenue is less than US$1m (₹21m revenue, or US$252k). Market cap is less than US$10m (₹162.6m market cap, or US$1.94m). Minor Risk Share price has been volatile over the past 3 months (8.1% average weekly change).
お知らせ • Aug 07Ortin Global Limited to Report Q1, 2025 Results on Aug 13, 2024Ortin Global Limited announced that they will report Q1, 2025 results on Aug 13, 2024
お知らせ • Jul 18Ortin Laboratories Limited Announces Resignation of Divya Purswani as Company Secretary and Compliance OfficerOrtin Laboratories Limited announced that Mrs. Divya Purswani has resigned from the post of company secretary and compliance officer of the company with effect from 18 July 2024 (After close of Business hours) due to her personal reasons.
Reported Earnings • Jun 04Full year 2024 earnings released: ₹9.89 loss per share (vs ₹0.12 loss in FY 2023)Full year 2024 results: ₹9.89 loss per share (further deteriorated from ₹0.12 loss in FY 2023). Revenue: ₹22.8m (down 62% from FY 2023). Net loss: ₹80.4m (loss widened ₹79.5m from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
お知らせ • May 24Ortin Laboratories Limited to Report Q4, 2024 Results on May 30, 2024Ortin Laboratories Limited announced that they will report Q4, 2024 results on May 30, 2024
Reported Earnings • Feb 14Third quarter 2024 earnings released: ₹3.43 loss per share (vs ₹0.56 profit in 3Q 2023)Third quarter 2024 results: ₹3.43 loss per share (down from ₹0.56 profit in 3Q 2023). Revenue: ₹1.37m (down 88% from 3Q 2023). Net loss: ₹27.9m (down ₹32.5m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 09Ortin Laboratories Limited Appoints Divya Purswani as Company Secretary and Compliance OfficerThe Board of Directors of Ortin Laboratories Limited at its meeting held on 9 February, 2024 has considered and approved the Appointment of Ms. Divya Purswani as Company Secretary and Compliance Officer of the Company with effect from February 09, 2024. Ms. Divya Purswani is a qualified Company Secretary, having working experience of around 2 years in the area of corporate laws and secretarial matters.
お知らせ • Feb 07Ortin Laboratories Limited to Report Q3, 2024 Results on Feb 13, 2024Ortin Laboratories Limited announced that they will report Q3, 2024 results on Feb 13, 2024
Buy Or Sell Opportunity • Jan 29Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 26% to ₹22.00. The fair value is estimated to be ₹18.02, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 65% over the last 3 years. Meanwhile, the company became loss making.
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Pottur Sujatha was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 16Second quarter 2024 earnings releasedSecond quarter 2024 results: ₹1.38 loss per share. Revenue: ₹2.65m (down 66% from 2Q 2023). Net loss: ₹11.2m (down ₹12.0m from profit in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 12Ortin Laboratories Limited Announces Executive ChangesOrtin Laboratories Limited announced that Mr. Harish Sharma has resigned from the post of Company Secretary and Compliance officer with effect from 10 November 2023, due to his personal reasons. (After close of Business hours). Mr. S. Murali Krishna Murthy, Managing Director will act as the Compliance Officer of the Company till the appointment of new Company Secretary and Compliance Officer.
お知らせ • Oct 11Ortin Laboratories Limited Appointment of Harish Sharma as Company SecretaryOrtin Laboratories Limited announced at the board meeting held on October 10, 2023, approved Appointment of Mr. Harish Sharma as Company Secretary and Compliance Officer of the Company with effect from 10.10.2023. Mr. Harish Sharma is a qualified Company Secretary, having working experience of around 4.5 years in the area of corporate laws and secretarial matters.
お知らせ • Sep 07Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2023Ortin Laboratories Limited, Annual General Meeting, Sep 30, 2023, at 11:00 Indian Standard Time.
Reported Earnings • Aug 16First quarter 2024 earnings releasedFirst quarter 2024 results: EPS: ₹0.02. Revenue: ₹15.7m (down 40% from 1Q 2023). Net income: ₹164.0k (up ₹4.43m from 1Q 2023). Profit margin: 1.0% (up from net loss in 1Q 2023). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 05Ortin Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023Ortin Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023
お知らせ • Jul 12Drugs Control Administration, Government of Telangana Cancels Manufacturing License of Ortin Laboratories LimitedOrtin Laboratories Limited announced that Drugs Control Administration, Government of Telangana vide its Order dated 03 July 2023 received by the Company on 11 July 2023 has cancelled the Company's Manufacturing License effective from July 11, 2023 forwant of upgradation of manufacturing facilities, infrastructure and recruiting expert technical team as per the provisions of Schedule-M of Drugs and Cosmetics Act, 1940 & rules made there under. Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any: Could not upgrade the manufacturing facilities, infrastructure and expert technical team as per the provisions of Schedule-M of Drugs and Cosmetics Act. 1940. Production of medicines is stopped and as a result there will be monetary impact to the tune of 75% of the turnover which is approximately INR 60 million. There is no other penalty involved or imposed on the company.
お知らせ • Jun 14Ortin Laboratories Limited Announces Resignation of Nitesh Kumar Sharma as Company Secretary/Compliance OfficerOrtin Laboratories Limited informed that Mr. Nitesh Kumar Sharma has resigned from the post of Company Secretary and Compliance officer of the company with effect from June 12, 2023 (After close of Business hours). Mr. S. Murali Krishna Murthy, Managing Director will act as the Compliance Officer of the Company till the appointment of new Company Secretary and Compliance Officer.
New Risk • Jun 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.8x net interest cover). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (₹61m revenue, or US$735k). Market cap is less than US$10m (₹186.9m market cap, or US$2.27m). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change).
Reported Earnings • Jun 03Full year 2023 earnings released: ₹0.08 loss per share (vs ₹0.49 loss in FY 2022)Full year 2023 results: ₹0.08 loss per share (improved from ₹0.49 loss in FY 2022). Revenue: ₹60.6m (down 26% from FY 2022). Net loss: ₹669.0k (loss narrowed 83% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Reported Earnings • Feb 16Third quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.11 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹0.56 (up from ₹0.11 loss in 3Q 2022). Revenue: ₹11.7m (down 30% from 3Q 2022). Net income: ₹4.56m (up ₹5.46m from 3Q 2022). Profit margin: 39% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
お知らせ • Feb 01Ortin Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023Ortin Laboratories Limited announced that they will report Q3, 2023 results at 3:30 PM, Indian Standard Time on Feb 14, 2023
Reported Earnings • Nov 20Second quarter 2023 earnings released: EPS: ₹0.01 (vs ₹0.07 in 2Q 2022)Second quarter 2023 results: EPS: ₹0.01. Revenue: ₹7.87m (down 66% from 2Q 2022). Net income: ₹808.0k (up 50% from 2Q 2022). Profit margin: 10% (up from 2.3% in 2Q 2022). The increase in margin was driven by lower expenses.
Reported Earnings • Aug 19First quarter 2023 earnings released: ₹0.05 loss per share (vs ₹0.11 profit in 1Q 2022)First quarter 2023 results: ₹0.05 loss per share (down from ₹0.11 profit in 1Q 2022). Revenue: ₹26.2m (up 32% from 1Q 2022). Net loss: ₹4.27m (down ₹5.18m from profit in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Reported Earnings • Jun 02Full year 2022 earnings released: ₹0.49 loss per share (vs ₹1.16 profit in FY 2021)Full year 2022 results: ₹0.49 loss per share (down from ₹1.16 profit in FY 2021). Revenue: ₹84.3m (up 2.5% from FY 2021). Net loss: ₹3.99m (down 142% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Executive Departure • Dec 05Whole Time Director Sanka Mohan Murthy has left the companyOn the 26th of November, Sanka Mohan Murthy's tenure as Whole Time Director ended after 10.8 years in the role. As of September 2021, Sanka Mohan still personally held only 13.62k shares (₹367k worth at the time). A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Oct 08Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₹30.85, the stock trades at a trailing P/E ratio of 58.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 14% over the past three years.
Reported Earnings • Jul 10Full year 2021 earnings released: EPS ₹1.16 (vs ₹0.69 loss in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: ₹82.2m (down 96% from FY 2020). Net income: ₹9.46m (up ₹15.1m from FY 2020). Profit margin: 12% (up from net loss in FY 2020). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Jun 16Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹36.30, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Negligible returns to shareholders over past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to ₹25.35, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 18x in the Pharmaceuticals industry in India. Total returns to shareholders of 35% over the past three years.
分析記事 • Jan 24Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention TodayLike a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Valuation Update With 7 Day Price Move • Jan 04Investor sentiment improved over the past weekAfter last week's 27% share price gain to ₹32.60, the stock is trading at a trailing P/E ratio of 22x, up from the previous P/E ratio of 17.3x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 19%.
Valuation Update With 7 Day Price Move • Dec 31Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₹30.00, the stock is trading at a trailing P/E ratio of 20.9x, up from the previous P/E ratio of 18x. This compares to an average P/E of 24x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 8.3%.
Is New 90 Day High Low • Dec 31New 90-day high: ₹30.00The company is up 54% from its price of ₹19.45 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period.
分析記事 • Dec 27Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Dec 03Market bids up stock over the past weekAfter last week's 17% share price gain to ₹25.60, the stock is trading at a trailing P/E ratio of 18x, up from the previous P/E ratio of 15.4x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 35%.
分析記事 • Nov 30Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?Most readers would already be aware that Ortin Laboratories' (NSE:ORTINLABSS) stock increased significantly by 12...
Is New 90 Day High Low • Nov 18New 90-day high: ₹23.15The company is up 4.0% from its price of ₹22.30 on 20 August 2020. The Indian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
分析記事 • Sep 15Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt LoadThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...